Dataset Information

An ERK biosensor identifies phosphatases regulating ERK pathway in tissue development and carcinoma cells

ABSTRACT: Extracellular signal-regulated kinases (ERKs) play essential roles in development and are implicated in numerous diseases. Phosphatases act as key regulators of ERK activation. To obtain a view of the phosphorylation network regulating ERK activity, we describe a binary approach using mammalian cell culture and forward genetic screens in a model organism. We analyzed a spectrum of phosphatases in human cells with ERK-SPARK reporters. Further validation of selected components in Drosophila revealed a functional map of ERK pathway phosphatases. EYA family phosphatases were selected and characterized as novel and critical regulators of ERK signaling in vivo and in mammalian cells. Chemical screens using phosphatase inhibitors showed that pharmacological inhibition of Drosophila Eyes Absent Homologue 2 (EYA2) promotes the progression of ERK-dependent carcinoma. The kinase reporter enabled high-throughput screening of genetic and pharmacological regulators under physiological and pathological condition, an important approach for investigating the regulation of kinase signaling.

ORGANISM(S): Homo Sapiens

SUBMITTER: Hai Huang

PROVIDER: PXD054658 | iProX | Wed Aug 07 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Similar Datasets

Project description:About 50% of human malignancies exhibit unregulated signalling through the Ras-ERK1/2 (ERK) pathway, as a consequence of activating mutations in members of Ras and Raf families. However, the quest for alternative Ras-ERK pathway-directed therapies is desirable. Upon phosphorylation ERK dimerize. We had previously demonstrated that dimerization is essential for ERK extranuclear but not nuclear signaling. Furthermore, by molecular biology approaches, we showed that specifically inhibiting ERK extranuclear component, by impeding ERK dimerization, is sufficient for curtailing tumor progression. Here, we have identified a small molecule inhibitor for ERK dimerization in vitro and in vivo that, without affecting ERK phosphorylation, prevents tumorigenesis driven by Ras-ERK pathway oncogenes, both in cellular and animal models. Importantly, this compound is unaffected by resistance-acquisition processes that hamper “classical” Ras-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two novel concepts in cancer therapy: 1) The blockade of sublocalization-specific sub-signals, rather than total signals, as a means of effectively counteracting oncogenic Ras-ERK signaling. 2) Targeting regulatory protein-protein interactions such as dimerization, rather than catalytic activities, within a signaling route, as an approach for producing effective anti-tumoral agents. Strategies aimed at preventing aberrant flux through this route remain an attractive option for therapeutic intervention in cancer. In this respect, drugs inhibiting the kinase activities of BRaf and MEK have yielded promising results. A375p cells treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours. mRNA from A375p cells was extrated using RNeasy mini kit (Qiagen, Germany) according to the manufacturer's instructions. Cells were previously treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours.

Dataset Information

An ERK biosensor identifies phosphatases regulating ERK pathway in tissue development and carcinoma cells

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets